The Prognostic Role of Tumor Marker CA-125 in B-Cell Non-Hodgkin's Lymphoma

Overview

Journal Iran J Cancer Prev

Specialty Oncology

Date 2015 Mar 31

PMID 25821570

Citations 4

Authors

Bahram Memar

Amir Aledavood

Soodabeh Shahidsales

Mitra Ahadi

Mahdi Farzadnia

Hamid Reza Raziee

Sedighe Noori

Naser Tayebi-Meybodi

Sakineh Amouian

Samira Mohtashami

Affiliations

Soon will be listed here.

Abstract

Background: B-cell non-Hodgkin's lymphoma (NHL) is a common malignancy of lymphoid tissues. Different types of NHL show various behaviors, prognoses, and responses to treatment. Evaluation of disease activity in NHL can be helpful in managing and even increasing the patient's survey.

Methods And Results: In total, 121 patients (76 males and 45 females), and their age range were 18-53 years, were evaluated in this study. The mean level of serum carbohydrate antigen 125 (CA-125) was 89.3±18.5 u/ml, ranging from 27 to 135 u/ml. There were significant differences in International Prognostic Index (IPI) score (p=0.002), stage of the disease (p=0.006), mortality rate (p=0.02), and relapse rate (p=0.04) between patients with serum CA-125 level <35 u/ml and patients with CA-125 level >35 u/ml.

Conclusion: CA-125 seems to be a useful and reliable tumor marker for monitoring a patient with NHL. It might be the time to consider CA-125 in staging, prognostic scoring, or decision making about NHL treatment.

Citing Articles

Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression.

Foda A, Atia T, Sakr H, Elnaghi K, Abdelhay W, Enan E J Evid Based Integr Med. 2023; 28:2515690X231198315.

PMID: 37654084 PMC: 10475264. DOI: 10.1177/2515690X231198315.

Primary ovarian lymphoma: A case report.

Gerrity C, Mercadel A, Alghamdi A, Huang M Gynecol Oncol Rep. 2023; 47:101212.

PMID: 37293350 PMC: 10245002. DOI: 10.1016/j.gore.2023.101212.

Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression.

Grasso L, Kline J, Nicolaides N Oncol Lett. 2021; 23(1):2.

PMID: 34820001 PMC: 8607236. DOI: 10.3892/ol.2021.13120.

Glucose restriction combined with chemotherapy decreases telomere length and cancer antigen-125 secretion in ovarian carcinoma.

Antoun S, Atallah D, Tahtouh R, Diab Assaf M, Moubarak M, Ayoub E Oncol Lett. 2020; 19(2):1338-1350.

PMID: 31966066 PMC: 6956372. DOI: 10.3892/ol.2019.11233.

References

Bonnet C, Beguin Y, Fassotte M, Seidel L, Luyckx F, Fillet G . Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol. 2007; 78(5):399-404. DOI: 10.1111/j.1600-0609.2007.00843.x. View

Abd El Gawad I, Shafik H . CA 125, a New Prognostic Marker for Aggressive NHL. J Egypt Natl Canc Inst. 2010; 21(3):209-17. View

Chadburn A, Abdul-Nabi A, Teruya B, Lo A . Lymphoid proliferations associated with human immunodeficiency virus infection. Arch Pathol Lab Med. 2013; 137(3):360-70. DOI: 10.5858/arpa.2012-0095-RA. View

Russo F, Lastoria S, Svanera G, Capobianco G, De Chiara A, di Francia R . Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007; 48(4):723-30. DOI: 10.1080/10428190601183710. View

Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ H, Kirgner I . Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003; 44(10):1733-8. DOI: 10.1080/1042819031000104079. View

Zacharos I, Efstathiou S, Petreli E, Georgiou G, Tsioulos D, Mastorantonakis S . The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma. Eur J Haematol. 2002; 69(4):221-6. DOI: 10.1034/j.1600-0609.2002.02771.x. View

Kobayashi H, Ida W, Terao T, Kawashima Y . Molecular characteristics of the CA 125 antigen produced by human endometrial epithelial cells: comparison between eutopic and heterotopic epithelial cells. Am J Obstet Gynecol. 1993; 169(3):725-30. DOI: 10.1016/0002-9378(93)90652-y. View

Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A . Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 1998; 82(3):576-82. View

Dilek I, Ayakta H, Demir C, Meral C, Ozturk M . CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol. 2005; 27(1):51-5. DOI: 10.1111/j.1365-2257.2004.00655.x. View

10.

Aledavood A, Nasiri M, Memar B, Shahidsales S, Raziee H, Ghafarzadegan K . Primary gastrointestinal lymphoma. J Res Med Sci. 2013; 17(5):487-90. PMC: 3634278. View

11.

Birgen D, Ertem U, Duru F, Sahin G, Yuksek N, Bozkurt C . Serum Ca 125 levels in children with acute leukemia and lymphoma. Leuk Lymphoma. 2005; 46(8):1177-81. DOI: 10.1080/10428190500096690. View

12.

Sanusi A, Zweers M, Weening J, de Waart D, Struijk D, Krediet R . Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis. Perit Dial Int. 2002; 21(5):495-500. View

13.

Batlle M, Ribera J, Oriol A, Pastor C, Mate J, Fernandez-Aviles F . Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. Leuk Lymphoma. 2005; 46(10):1471-6. DOI: 10.1080/10428190500204781. View

14.

Shustik J, Quinn M, Connors J, Gascoyne R, Skinnider B, Sehn L . Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2010; 22(5):1164-1169. DOI: 10.1093/annonc/mdq574. View